急性虚血性脳卒中治療の世界市場レポート 2025年

急性虚血性脳卒中治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）9.2％で143億8,000万米ドルに成長します。予測期間の成長は、オンライン薬局への嗜好の増加、心血管疾患の増加、コレステロール値の上昇、疾患の有病率の上昇、虚血性脳卒中の有病率の上昇に起因することができます。予測期間の主要動向には、医療技術の進歩、人工知能の統合、機械学習の統合、神経学の進歩、技術的に先進的診断法の採用などがあります。

高血圧の有病率の増加は、今後数年間の急性虚血性脳卒中治療市場の成長を促進すると予想されます。高血圧は、動脈壁に対する血液の力が常に高いままである状態であり、心臓病、脳卒中、その他の健康問題のリスクを高めています。この高血圧の増加は、人口の高齢化と肥満率の上昇が主要原因です。急性虚血性脳卒中治療は、脳卒中に関連する合併症を治療し、血圧上昇と関連することが多い脳血管障害を予防することにより、高血圧を管理するのに役立ちます。例えば、2023年5月、英国のNational Health Service Englandは、米国では成人の約30％が高血圧症であり、15％が未治療であると報告しました。また、高血圧の有病率は年齢とともに増加し、16～44歳の成人では9％、65歳以上では60％に達します。このように、高血圧の罹患率の増加が急性虚血性脳卒中治療市場の拡大に拍車をかけています。

急性虚血性脳卒中治療市場の主要企業は、エキソソームベースの治療などの革新的なソリューションを通じて医療技術を進歩させ、治療効果と患者の転帰を高めています。エクソソームベースの治療法は、細胞から放出される小さな細胞外小胞（直径30～150nm）であるエクソソームの利用に焦点を当てた新しいアプローチであり、細胞間コミュニケーションに役割を果たしています。例えば、2024年1月、米国を拠点とする神経エクソソームプラットフォームの開発企業アルナバイオ社は、AB126の治験薬申請をFDAから承認されました。これは、急性虚血性脳卒中を対象としたヒト臨床検査に入る最初のエクソソームベースの治療法となります。血栓除去術後の予後不良患者を対象に、AB126の安全性、忍容性、予備的有効性を評価するため、2024年初めに第1b/2a相臨床検査を開始する予定です。独自の神経幹細胞に由来するAB126は、前臨床検査で抗炎症作用と神経保護作用を示し、血液脳関門を通過することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の急性虚血性脳卒中治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性虚血性脳卒中治療市場：成長率分析
• 世界の急性虚血性脳卒中治療市場の実績：規模と成長、2019～2024年
• 世界の急性虚血性脳卒中治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の急性虚血性脳卒中治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性虚血性脳卒中治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血栓溶解療法
• 降圧治療
• 抗血小板治療
• 抗凝固薬
• 世界の急性虚血性脳卒中治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 世界の急性虚血性脳卒中治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の急性虚血性脳卒中治療市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 外来手術センター
• 診断センター
• 世界の急性虚血性脳卒中治療市場、血栓溶解療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 組織プラスミノーゲン活性化因子（tPA）
• ウロキナーゼ
• 世界の急性虚血性脳卒中治療市場、降圧治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシンII受容体拮抗薬（ARB）
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 利尿剤
• 世界の急性虚血性脳卒中治療市場、抗血小板治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アスピリン
• クロピドグレル
• チカグレロル
• ジピリダモール
• シロスタゾール
• 世界の急性虚血性脳卒中治療市場、抗凝固薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ビタミンK拮抗薬
• 直接経口抗凝固薬（DOAC）
• ヘパリン

第7章 地域別・国別分析

• 世界の急性虚血性脳卒中治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の急性虚血性脳卒中治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性虚血性脳卒中治療市場：競合情勢
• 急性虚血性脳卒中治療市場：企業プロファイル
  • Johnson & Johnson
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Abbott Laboratories

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Medtronic plc
• Eli Lilly and Company
• Amgen Inc.
• Stryker Corporation
• Teva Pharmaceutical Industries Limited
• Merck & Co. Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Biogen Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Genentech Inc.
• NoNO Inc.
• Athersys Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 急性虚血性脳卒中治療市場、2029年：新たな機会を提供する国
• 急性虚血性脳卒中治療市場、2029年：新たな機会を提供するセグメント
• 急性虚血性脳卒中治療市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Acute ischemic stroke therapeutics refer to the medical treatments and interventions used to manage and treat ischemic stroke, which occurs when a blood clot obstructs or narrows an artery leading to the brain, resulting in a sudden reduction of blood flow and oxygen to brain tissue. The primary objective of these therapeutics is to restore blood flow to the affected brain area as quickly as possible to reduce brain damage and enhance outcomes.

The main types of acute ischemic stroke therapeutics include thrombolytic therapeutics, antihypertensive therapeutics, antiplatelet therapeutics, and anticoagulants. Thrombolytic therapeutics are medications aimed at dissolving blood clots and reestablishing normal blood flow in conditions such as heart attacks, strokes, and pulmonary embolisms. These medications can be administered orally or parenterally and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in settings such as hospitals, ambulatory surgical centers, and diagnostic centers.

The acute ischemic stroke therapeutics market research report is one of a series of new reports from The Business Research Company that provides acute ischemic stroke therapeutics market statistics, including acute ischemic stroke therapeutics industry global market size, regional shares, competitors with acute ischemic stroke therapeutics market share, detailed acute ischemic stroke therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the acute ischemic stroke therapeutics industry. This acute ischemic stroke therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute ischemic stroke therapeutics market size has grown strongly in recent years. It will grow from $9.24 $ billion in 2024 to $10.12 $ billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to an increase in the number of patients, a rise in the geriatric population, a growing prevalence of obesity, a rising prevalence of ischemic stroke, and rising hypertension.

The acute ischemic stroke therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.38 $ billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing preference for online pharmacies, increasing cardiovascular diseases, increasing cholesterol levels, rising prevalence of diseases, and rising prevalence of ischemic stroke. Major trends in the forecast period include advancements in medical technology, the integration of artificial intelligence, the integration of machine learning, advancements in neurology, and the adoption of technologically advanced diagnostics.

The increasing prevalence of hypertension is expected to drive the growth of the acute ischemic stroke therapeutics market in the coming years. Hypertension, or high blood pressure, is a condition where the force of blood against the artery walls remains consistently high, raising the risk of heart disease, stroke, and other health issues. This rise in hypertension is largely attributed to an aging population and higher obesity rates. Acute ischemic stroke therapies help manage hypertension by treating stroke-related complications and preventing further cerebrovascular damage, which is often linked to elevated blood pressure. For example, in May 2023, the UK's National Health Service England reported that about 30% of adults in the US had hypertension, with 15% having untreated cases. The prevalence of hypertension also increases with age, ranging from 9% in adults aged 16-44 to 60% in those aged 65 and older. Thus, the growing incidence of hypertension is fueling the expansion of the acute ischemic stroke therapeutics market.

Leading companies in the acute ischemic stroke therapeutics market are advancing medical technologies through innovative solutions such as exosome-based therapy to enhance treatment efficacy and patient outcomes. Exosome-based therapy is a novel approach focusing on using exosomes, small extracellular vesicles (30-150 nm in diameter) released by cells, which play a role in cell-to-cell communication. For instance, in January 2024, Aruna Bio, a US-based developer of neural exosome platforms, received FDA clearance for its investigational new drug application for AB126. This marks the first exosome-based therapy to enter human clinical trials targeting acute ischemic stroke. A Phase 1b/2a clinical trial is scheduled to begin in early 2024 to evaluate the safety, tolerability, and preliminary efficacy of AB126 in patients with poor prognosis following thrombectomy. Derived from proprietary neural stem cells, AB126 has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies and is capable of crossing the blood-brain barrier.

In June 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for an undisclosed amount. This acquisition aims to enhance Johnson & Johnson's immunology portfolio by integrating innovative bispecific antibodies to address unmet needs in atopic dermatitis and asthma. It also seeks to develop advanced therapeutics through dual targeting of disease pathways. Proteologix Inc., a US-based provider of drug discovery and development solutions, specializes in targeted protein degradation.

Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC

North America was the largest region in the acute ischemic stroke therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute ischemic stroke therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute ischemic stroke therapeutics market consists of revenues earned by entities by providing services such as mechanical thrombectomy, antiplatelet therapy, rehabilitation services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute ischemic stroke therapeutics market also includes sales of antiplatelet agents, mechanical thrombectomy devices, neuroprotective agents, and anticoagulants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Ischemic Stroke Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute ischemic stroke therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute ischemic stroke therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute ischemic stroke therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Thrombolytic Therapeutics; Antihypertensive Therapeutics; Antiplatelet Therapeutics; Anticoagulants
• 2) By Route Of Administration: Oral; Parenteral
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Hospitals; Ambulatory Surgical Center; Diagnostic Centers
• Subsegments:
• 1) By Thrombolytic Therapeutics: Tissue Plasminogen Activators (tPA); Urokinase
• 2) By Antihypertensive Therapeutics: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Beta Blockers; Calcium Channel Blockers; Diuretics
• 3) By Antiplatelet Therapeutics: Aspirin; Clopidogrel; Ticagrelor; Dipyridamole; Cilostazol
• 4) By Anticoagulants: Vitamin K Antagonists; Direct Oral Anticoagulants (DOACs); Heparins
• Companies Mentioned: Johnson & Johnson; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Ischemic Stroke Therapeutics Market Characteristics

3. Acute Ischemic Stroke Therapeutics Market Trends And Strategies

4. Acute Ischemic Stroke Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Ischemic Stroke Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Ischemic Stroke Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Ischemic Stroke Therapeutics Market Growth Rate Analysis
• 5.4. Global Acute Ischemic Stroke Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Ischemic Stroke Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Ischemic Stroke Therapeutics Total Addressable Market (TAM)

6. Acute Ischemic Stroke Therapeutics Market Segmentation

• 6.1. Global Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thrombolytic Therapeutics
• Antihypertensive Therapeutics
• Antiplatelet Therapeutics
• Anticoagulants
• 6.2. Global Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Acute Ischemic Stroke Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Center
• Diagnostic Centers
• 6.5. Global Acute Ischemic Stroke Therapeutics Market, Sub-Segmentation Of Thrombolytic Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tissue Plasminogen Activators (tPA)
• Urokinase
• 6.6. Global Acute Ischemic Stroke Therapeutics Market, Sub-Segmentation Of Antihypertensive Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Beta Blockers
• Calcium Channel Blockers
• Diuretics
• 6.7. Global Acute Ischemic Stroke Therapeutics Market, Sub-Segmentation Of Antiplatelet Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Clopidogrel
• Ticagrelor
• Dipyridamole
• Cilostazol
• 6.8. Global Acute Ischemic Stroke Therapeutics Market, Sub-Segmentation Of Anticoagulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin K Antagonists
• Direct Oral Anticoagulants (DOACs)
• Heparins

7. Acute Ischemic Stroke Therapeutics Market Regional And Country Analysis

• 7.1. Global Acute Ischemic Stroke Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Ischemic Stroke Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Ischemic Stroke Therapeutics Market

• 8.1. Asia-Pacific Acute Ischemic Stroke Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Ischemic Stroke Therapeutics Market

• 9.1. China Acute Ischemic Stroke Therapeutics Market Overview
• 9.2. China Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Ischemic Stroke Therapeutics Market

• 10.1. India Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Ischemic Stroke Therapeutics Market

• 11.1. Japan Acute Ischemic Stroke Therapeutics Market Overview
• 11.2. Japan Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Ischemic Stroke Therapeutics Market

• 12.1. Australia Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Ischemic Stroke Therapeutics Market

• 13.1. Indonesia Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Ischemic Stroke Therapeutics Market

• 14.1. South Korea Acute Ischemic Stroke Therapeutics Market Overview
• 14.2. South Korea Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Ischemic Stroke Therapeutics Market

• 15.1. Western Europe Acute Ischemic Stroke Therapeutics Market Overview
• 15.2. Western Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Ischemic Stroke Therapeutics Market

• 16.1. UK Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Ischemic Stroke Therapeutics Market

• 17.1. Germany Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Ischemic Stroke Therapeutics Market

• 18.1. France Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Ischemic Stroke Therapeutics Market

• 19.1. Italy Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Ischemic Stroke Therapeutics Market

• 20.1. Spain Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Ischemic Stroke Therapeutics Market

• 21.1. Eastern Europe Acute Ischemic Stroke Therapeutics Market Overview
• 21.2. Eastern Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Ischemic Stroke Therapeutics Market

• 22.1. Russia Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Ischemic Stroke Therapeutics Market

• 23.1. North America Acute Ischemic Stroke Therapeutics Market Overview
• 23.2. North America Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Ischemic Stroke Therapeutics Market

• 24.1. USA Acute Ischemic Stroke Therapeutics Market Overview
• 24.2. USA Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Ischemic Stroke Therapeutics Market

• 25.1. Canada Acute Ischemic Stroke Therapeutics Market Overview
• 25.2. Canada Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Ischemic Stroke Therapeutics Market

• 26.1. South America Acute Ischemic Stroke Therapeutics Market Overview
• 26.2. South America Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Ischemic Stroke Therapeutics Market

• 27.1. Brazil Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Ischemic Stroke Therapeutics Market

• 28.1. Middle East Acute Ischemic Stroke Therapeutics Market Overview
• 28.2. Middle East Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Ischemic Stroke Therapeutics Market

• 29.1. Africa Acute Ischemic Stroke Therapeutics Market Overview
• 29.2. Africa Acute Ischemic Stroke Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Ischemic Stroke Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Ischemic Stroke Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Ischemic Stroke Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Acute Ischemic Stroke Therapeutics Market Competitive Landscape
• 30.2. Acute Ischemic Stroke Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Acute Ischemic Stroke Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. F. Hoffmann-La Roche Ltd.
• 31.3. Medtronic plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Stryker Corporation
• 31.7. Teva Pharmaceutical Industries Limited
• 31.8. Merck & Co. Inc.
• 31.9. Otsuka Pharmaceutical Co. Ltd.
• 31.10. Biogen Inc.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Eisai Co. Ltd.
• 31.13. Genentech Inc.
• 31.14. NoNO Inc.
• 31.15. Athersys Inc.

32. Global Acute Ischemic Stroke Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Ischemic Stroke Therapeutics Market

34. Recent Developments In The Acute Ischemic Stroke Therapeutics Market

35. Acute Ischemic Stroke Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Acute Ischemic Stroke Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Ischemic Stroke Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Ischemic Stroke Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer